New Delhi : Drug major Sun Pharmaceutical Industries is said to be in race to acquire US-based eye care firm InSite Vision Inc at a price of USD 0.35 per share. “InSite’s Board of Directors has determined that the previously announced unsolicited offer from a global pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at USD 0.35 per share in an all- cash transaction constitutes a ‘Company Superior Proposal’ as defined in InSite’s previously announced definitive agreement with QLT Inc dated as of August 26, 2015,” the US-based firm said. The company, however, did not name the suitor but reports suggested it was Sun Pharmaceuticals.

When contacted a Sun Pharma spokesperson told PTI: “We don’t comment on market speculations.”

(For all the latest News, Mumbai, Entertainment, Cricket, Business and Featured News updates, visit Free Press Journal. Also, follow us on Twitter and Instagram and do like our Facebook page for continuous updates on the go)

Free Press Journal